Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Experimental and Molecular Therapeutics

Abstract 718: The effects of trastuzumab, paclitaxel, and carboplatin on HER2-positive cancer stem cells that are isolated from primary breast cancer cultures: a preliminary report

Mehmet Artac, Gozde Kayadibi, Ayca Ceylan, Meltem Demirel Kars, Hasibe Artac, Murat Cakır, Cem Boruban, Ahmet Tekin, Lema Tavlı and Adil Kartal
Mehmet Artac
Necmettin Erbakan University Meram Medical Faculty Department of Medical Oncology, Konya, Turkey;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gozde Kayadibi
Advanced Technology Research and Application Center, Selcuk University, Konya, Turkey;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ayca Ceylan
Selcuk University Medical Faculty Department of Pediatric Allergy and Immunology, Konya, Turkey;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meltem Demirel Kars
Advanced Technology Research and Application Center, Selcuk University, Konya, Turkey;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hasibe Artac
Selcuk University Medical Faculty Department of Pediatric Allergy and Immunology, Konya, Turkey;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Murat Cakır
Necmettin Erbakan University Meram Medical Faculty Department of General Surgery, Konya, Turkey;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cem Boruban
Necmettin Erbakan University Meram Medical Faculty Department of Medical Oncology, Konya, Turkey;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ahmet Tekin
Necmettin Erbakan University Meram Medical Faculty Department of General Surgery, Konya, Turkey;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lema Tavlı
Necmettin Erbakan University Meram Medical Faculty Department of Pathology, Konya, Turkey.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adil Kartal
Necmettin Erbakan University Meram Medical Faculty Department of General Surgery, Konya, Turkey;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM2015-718 Published August 2015
  • Article
  • Info & Metrics
Loading
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA

Abstract

Introduction:

It is generally accepted that trastuzumab has only effective in HER2+ breast cancer patients who have HER2 gene amplification or HER2 over expression. On the other hand, trastuzumab resistance is a problem in HER2+ patients. Our aim is to investigate the effects of trastuzumab, paclitaxel and carboplatin on cancer stem cells which is isolated from primary breast cancer cultures.

Methods:

Tumor tissue was obtained in the routine surgery of a breast cancer patient who was HER2+ by immunohistochemistry. Primary breast cancer culture were established. CD44+CD24- and ALDH+ breast cancer stem cells were sorted by flowcytometry from these culture. HER2 receptor status of the sorted cells was also determined by flowcytometry. HER2+ and HER2- breast cancer stem cells were treated with trastuzumab, paclitaxel and carboplatin, and combination of these drugs by checker board microplate method for 96 h. For all of these breast cancer stem cell subgroups, the responses to the drugs were determined.

Results:

Breast cancer stem cells were isolated from a HER2+ breast cancer patient. The cell sorting analysis results demonstrates that 43% of the population is CD44+CD24- and 22% of the population is ALDH+. CD44+CD24- breast cancer stem cell subpopulation contains 84% HER2+ and 16% HER2- cells. Carboplatin has the highest antiproliferative effect on cancer stem cells among the three drugs which means carboplatin application resulted in the lowest IC50 values in all subgroups (IC50: 0.26 μM- 0.41 μM). HER2- cancer stem cells are more resistant to the drugs (1.5- 2 fold resistance) than HER2+ subcultures. Although combination of drugs exerted synergistic effect on the subcultures, ‘breast cancer stem cells’ were found to be more resistant to the combination therapy by exhibiting higher proliferation in drug combinations.

Conclusions:

HER2- cancer stem cells may be one of reason for trastuzumab resistance in HER2+ breast cancer patients. The result of this experimental study may be used to suggest new treatment strategies in HER2+ breast cancer patients.

Citation Format: Mehmet Artac, Gozde Kayadibi, Ayca Ceylan, Meltem Demirel Kars, Hasibe Artac, Murat Cakır, Cem Boruban, Ahmet Tekin, Lema Tavlı, Adil Kartal. The effects of trastuzumab, paclitaxel, and carboplatin on HER2-positive cancer stem cells that are isolated from primary breast cancer cultures: a preliminary report. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 718. doi:10.1158/1538-7445.AM2015-718

  • ©2015 American Association for Cancer Research.
Previous
Back to top
Cancer Research: 75 (15 Supplement)
August 2015
Volume 75, Issue 15 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract 718: The effects of trastuzumab, paclitaxel, and carboplatin on HER2-positive cancer stem cells that are isolated from primary breast cancer cultures: a preliminary report
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract 718: The effects of trastuzumab, paclitaxel, and carboplatin on HER2-positive cancer stem cells that are isolated from primary breast cancer cultures: a preliminary report
Mehmet Artac, Gozde Kayadibi, Ayca Ceylan, Meltem Demirel Kars, Hasibe Artac, Murat Cakır, Cem Boruban, Ahmet Tekin, Lema Tavlı and Adil Kartal
Cancer Res August 1 2015 (75) (15 Supplement) 718; DOI: 10.1158/1538-7445.AM2015-718

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract 718: The effects of trastuzumab, paclitaxel, and carboplatin on HER2-positive cancer stem cells that are isolated from primary breast cancer cultures: a preliminary report
Mehmet Artac, Gozde Kayadibi, Ayca Ceylan, Meltem Demirel Kars, Hasibe Artac, Murat Cakır, Cem Boruban, Ahmet Tekin, Lema Tavlı and Adil Kartal
Cancer Res August 1 2015 (75) (15 Supplement) 718; DOI: 10.1158/1538-7445.AM2015-718
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Experimental and Molecular Therapeutics

  • Abstract SY14-03: Anaplastic lymphoma kinase (ALK): Normal biology and role in hematopoietic malignancies
  • Abstract SY18-01: Targeting the p53-MDM2 interaction for cancer therapy
  • Abstract SSY01-04: Discovery and validation of genome-wide genetic signatures of chemotherapy susceptibility: A translational model
Show more 3

Poster Presentations - Proffered Abstracts

  • Abstract LB-236: Risk of tMDS/AML after chemotherapy for first primary lymphoid malignancy, 2000-2013
  • Abstract LB-001: Impact of direct physician engagement with racial/ethnic minorities for oncology clinical trial access and accrual model
  • Abstract LB-107: EV-TRACK: transparent reporting and centralizing knowledge of extracellular vesicles to support the validation of extracellular vesicle biomarkers in cancer research
Show more 3

Poster Presentations - Therapeutic Resistance in Hormone-Sensitive Cancers

  • Abstract 723: GRB7 promotes doxorubicin resistance in triple-negative breast cancer cells via multiple signaling pathways
  • Abstract 737: Clonal evolution of the HER2 L755S mutation as a mechanism of acquired HER-targeted therapy resistance
  • Abstract 725: Restoration of miR-100 sensitizes luminal A breast cancer to paclitaxel treatment by targeting mTOR
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement